Brain Cancer Clinical Trials

UCI 10-10
Collecting Brain Tumor Specimens for Glioma Vaccine (Bota)

UCI 12-18
Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments (Bota)

EAF151
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab In Patients with Recurrent Glioblastoma (Chow)

ACOSOG A221101
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme (Bota)

UCI 15-79
Phase II Open-label randomized study of radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 brain metastases from NSCLC (Bota)

UCI 16-74
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Bota)

** opening soon
**Brain Cancer Clinical Trials**

UCI 16-55  
Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma (Bota)

NRG BN001  
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (Kong)

NRG BN003  
Ph III Trial of observation versus irradiation for a gross totally resected grade II meningioma (Kong)

ALLIANCE-A071601  
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas (Bota)

UCI 17-115**  
Phase II Trial Of AV-GBM-1 As An Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation In Patients With Newly Diagnosed Glioblastoma (Bota)

UCI 17-88  
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with RT and TMZ in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (Bota)

UCI 17-88**  
Ph II Study of Optune in Bevacizumab-Naïve Subjects w/ Recurrent WHO grade III Malignant Astrocytoma (Bota)

RTOG 3503  
Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma (Kong)

UCI 14-58**  
Ph1, Multicenter, Open-Label, Dose Escalation, Combination Study Of Marizomib And Bevacizumab In Bevacizumab-Naïve Subjects With GradeIV MG Followed By Ph2 Studies Of Single Agent MRZ And Combination MRZ And Bevacizumab, And Ph1 Dose-Escalation Study Of Enterally-Administered MRZ With Bevacizumab. (Bota)

ECOG-EAY131  
**Some Cohorts Suspended**  
Molecular Analysis for Therapy Choice – MATCH (Bota)

SWOG S1609  
**Some cohorts suspended**  
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors – DART (Bota)

UCI 16-22  
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflomithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur after Irradiation and Adjuvant Temozolomide Chemotherapy (Bota)

UCI 17-35  
Ph II Trial of DSP-7888 Dosing Emulsion Combo w/ Bev vs Bev Alone for Glioblastoma (Kong)

ALLIANCE A071401  
**SUSPENDED**  
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations (Bota)

UCI 13-14  
Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in treatment of recurrent/progressive GBM & gliosarcoma patients (WHO grade IV malignant gliomas) (Bota)

UCI 15-35  
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent GBM or Anaplastic Astrocytoma (Bota)

** opening soon